Following a full submission:
rilpivirine (Edurant®) is accepted for use within NHS Scotland.
Indication under review: rilpivirinein combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type1 (HIVâ€‘1) infection in antiretroviral treatmentâ€‘naïve adult patients with a viral load ≤100,000 HIVâ€‘1 RNA copies/mL.
The non-inferiority of rilpivirine over another non-nucleoside reverse transcriptase inhibitor (when given in combination with two nucleoside reverse transcriptase inhibitors) for virological response was demonstrated in two phase III, comparative, multi-centre studies in antiretroviral treatment-naïve patients.
Download detailed advice207KB (PDF)
- Medicine name:
- rilpivirine (Edurant)
- SMC ID:
- In combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (HIV 1) infection in antiretroviral treatment naïve adult patients with a viral load â‰¤ 100,000 HIV 1 RNA copies/ml.
- Pharmaceutical company
- Tibotec (Janssen-Cilag Ltd)
- BNF chapter
- Submission type
- Date advice published
- 13 February 2012